Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Effect of Leptin Treatment in a Mouse Model of Tdp-43 Proteinopathy

Version 1 : Received: 31 March 2021 / Approved: 2 April 2021 / Online: 2 April 2021 (11:09:21 CEST)

How to cite: Ferrer-Donato, A.; Contreras, A.; Fernandez, P.; Fernandez-Martos, C.M. Effect of Leptin Treatment in a Mouse Model of Tdp-43 Proteinopathy. Preprints 2021, 2021040041 (doi: 10.20944/preprints202104.0041.v1). Ferrer-Donato, A.; Contreras, A.; Fernandez, P.; Fernandez-Martos, C.M. Effect of Leptin Treatment in a Mouse Model of Tdp-43 Proteinopathy. Preprints 2021, 2021040041 (doi: 10.20944/preprints202104.0041.v1).

Abstract

Amyotrophic Lateral Sclerosis (ALS) is an irreversible neurodegenerative disease with no known cure. Recent studies suggest a strong metabolic component in ALS pathogenesis and have shown an inverse relationship between leptin levels and ALS progression, although the effects of leptin as a treatment have not yet been studied. Therefore, we aim to examine whether the acute treatment with leptin has beneficial effects on brain pathology and cognitive function in the transgenic TDP43A315T line of ALS. Mice were treated intranasally (IN) with 0.03mg/kg of leptin or vehicle (VH) daily for 7 days. Data showed a progressive decline in body weight and motor coordination in TDP43A315T mice. Moreover, Lep-treated TDP43A315T mice showed an earlier disease onset, along with an improvement in motor performance. Altered levels of some of the adipokines and metabolic proteins studied were found in TDP43A315T mice, which were differently expressed among Lep-treated and VH-treated animals. Furthermore, some correlations were found among the serum levels of this proteins in WT and TDP43A315T mice. As far as we know, this is the first pilot study to provide evidence of the therapeutic effect of leptin treatment in a mice model of ALS, although further studies are needed to expound on the underlying mechanisms.

Subject Areas

Leptin; Metabolism; Amyotrophic Lateral Sclerosis (ALS); TAR DNA binding protein (TDP-43).

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.